Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)
Phase I/II Administration of CMV (Cytomegalovirus)-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)
Sponsor: Baylor College of Medicine
Terminated
poor accrual
Other terminated trials from Baylor College of Medicine
This PHASE1/PHASE2 trial investigates Brain Cancer and GBM and is currently terminated or withdrawn. Baylor College of Medicine leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2021 — Apr 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .